Kyowa Kirin Publishes “Integrated Report 2025” – Highlights the Evolution of Value Creation and Enhancement toward Vision 2030 –
June 9, 2026
Tokyo, Japan, June 9, 2026 --Kyowa Kirin Co., Ltd. (President and CEO: Abdul Mullick, “Kyowa Kirin”, TSE: 4151) today announced that it published its “Integrated Report 2025,” which outlines the Kyowa Kirin Group’s initiatives for sustainable value creation and its medium- to long-term outlook, on its Investor Relations (IR) website.
Integrated Report 2025: https://ir.kyowakirin.com/en/library/annual.html
The Kyowa Kirin Group is committed to the continuous creation of life-changing value that brings smiles to people facing illness, as a Japan-based global specialty pharmaceutical company, driven by a passion for innovation and the power of diverse teams. This report is intended to provide shareholders, investors, and other stakeholders with a comprehensive overview of the Group’s management strategies toward the realization of Vision 2030, as well as its initiatives for sustainable value creation, from both financial and non-financial perspectives. Through this report, Kyowa Kirin hopes to further deepen stakeholders’ understanding of our aspirations and our efforts to enhance corporate value over the medium to long term.
- Key Contents of Integrated Report 2025
-
- CEO Message: Turning the page to a new chapter of our growth story, Vision 2030 and Beyond, as a Japan-based Global Specialty Pharmaceutical (GSP) company
- Discussion with Outside Directors: Pioneering Efforts to Enhance Corporate Value through a New Governance Structure
- Review of the 2021–2025 Medium-Term Business Plan and strategies to realize Vision 2030
- Evolution of Corporate Governance, including the transition to a Company with an Audit and Supervisory Committee and the introduction of the new C-suite Executive structure
- Patient-centric value creation and initiatives in business operations and research & development
- Foundation for value creation through human capital, organization, and corporate culture
- Sustainability initiatives supporting sustainable value creation, including responses to environmental and social issues
The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies
- About Kyowa Kirin
- Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology and rare diseases. A shared commitment to Kyowa Kirin’s values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at http://www.kyowakirin.com/.
